Table 3.

Modified parameter values for comparator scenario of near-universal penetration and utilization of pediatric FDCs (compared with MAP-IT model baseline values)

Model parameter		Baseline scenario		Modified scenario for near-universal penetration and utilization
		Public (%)	Private (%)	Public (%)	Private (%)
Presumptive treatment for drug-sensitive TB with pediatric FDCs	Penetration	90	90	98	98
	Utilization	40	40	98	98
Clinical treatment for confirmed drug-sensitive TB with pediatric FDCs	Penetration	90	90	98	98
	Utilization	65	65	98	98